Drug intelligence / Profile preview

TLA Gut

Development stage: Unknown
Lead developer: TLA Targeted Immunotherapies

Overview

TLA Gut is an investigational therapeutic product evaluated for the treatment of acute exacerbation of ulcerative colitis (UC). It is currently being studied in clinical trials as having two dose regimens. The mechanism of action is likely targeted immunomodulation within the gut, but specific molecular details (e.g., target or modality such as antibody, small molecule, etc.) are not published in available sources. Its primary indication is acute exacerbation of ulcerative colitis[4].

Brand names: TLA Gut
Other names: TLA Gut

Beyond the preview

Go deeper on TLA Gut.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TLA Gut.

Explore the full profile